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The rodent model for multiple sclerosis, experimental allergic (autoimmune) encephalomyelitis (EAE), has been
used to dissect molecular mechanisms of the autoimmune inﬂammatory response, and hence to devise and test
new therapies for multiple sclerosis. Clearly, artiﬁcial immunization against myelin may not necessarily reproduce
all the pathogenetic mechanisms operating in the human disease, but most therapies tested in multiple sclerosis
patientsareneverthelessbasedonconceptsderivedfromstudiesinEAE.Unfortunately,severaltreatments,though
successful in pre-clinical EAE trials, were either less effective in patients, worsened disease or caused unexpected,
severe adverse events, as we review here. These discrepancies must, at least in part, be due to genetic and
environmental differences, but the precise underlying reasons are not yet clear. Our understanding of EAE patho-
genesis is still incomplete and so, therefore, are any implications for drug development in these models. Here, we
suggestsomepotentialexplanationsbasedonnewthinkingaboutkeypathogenicconceptsanddifferencesthatmay
limit extrapolation from EAE to multiple sclerosis. To try to circumvent these rodent–human dissimilarities more
systematically, we propose that pre-clinical trials should be started in humanized mouse models.
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Introduction
Multiple sclerosis is the commonest neurological disease of
young adults, afﬂicting at least 350 000 individuals in North
America and 500 000 in Europe (Haﬂer et al., 2005; Sospedra
and Martin, 2005). Although multiple sclerosis does not
usually shorten life expectancy, its socio-economic burden
in young adults is second only to trauma (Sospedra and
Martin, 2005). Its clinical signs and symptoms are very
variable and depend on the parts of the CNS it affects,
that is, the brain and spinal cord, and include motor, sensory,
autonomic and cognitive disabilities (Noseworthy et al.,
2000a). It can run at least three clinical courses: (i)
relapsing–remitting (RR) multiple sclerosis, which is most
frequent (85%) and characterized by discrete attacks
(exacerbations) and subsequent periods of clinical stability.
In most relapsing multiple sclerosis patients, (ii) a secondary
progressive (SP) phase ensues, with continuously increasing
deﬁcits. About 10–15% of multiple sclerosis patients develop
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 steadily increasing neurological deﬁcits from onset, (iii) the
primary-progressive subtype (Noseworthy et al., 2000a).
Neuropathologically, CNS tissue from multiple sclerosis
patients shows discrete lesions (predominantly in the white
matter) with inﬂammatory inﬁltrates, demyelination, astro-
gliosis and early axonal damage. Again, there is considerable
heterogeneity in composition of cellular inﬁltrates and in
involvement of antibodies and complement (Lassmann
et al., 2001). Multiple sclerosis is widely considered an
autoimmune demyelinating disease, and the inﬂammatory
inﬁltrates as pathogenically primary events. Its aetiology
remains a mystery, but infectious agents have long been
suspected as triggers (Marrie, 2004). The evidence for an
autoimmune reaction targeting myelin is strong but not
deﬁnitive. There are, for example, descriptions of primary
oligodendrocyte apoptosis with microglial activation in
early multiple sclerosis lesions in the absence of lymphocytes
or myelin phagocytosis (Barnett and Prineas, 2004). Further,
the decreasing inﬂammatory activity that is seen by MRI during
the SP phase has led to the assumption that the pathology is
inﬂammatory at ﬁrst and degenerative later. Despite these uncer-
tainties, it is generally accepted that multiple sclerosis involves an
autoimmune reaction by myelin-speciﬁc CD4
+ T helper 1 (TH1)
cells, which initiate the neuropathology (Haﬂer et al., 2005;
Sospedra and Martin, 2005). This notion is based on the
cellular composition of CNS- and CSF-inﬁltrating cells
(Hauser et al., 1986), on genetic studies in multiple sclerosis
(Dyment et al., 2004) and on one animal model of multiple
sclerosis, experimental allergic (autoimmune)encephalomye-
litis (EAE) (Zamvil and Steinman, 1990).
Dissecting the pathogenesis of a complex disease in man is
fraught with many problems, particularly those associated
with clinical and genetic heterogeneity. Not surprisingly,
most of our current thinking about multiple sclerosis
stems from EAE. This model originated from vaccination
with rabies-infected rabbit spinal cord by Louis Pasteur
(from 1885). About 1 in 1000 vaccinees had ‘neuroparalytic
incidents’; this acute demyelinating disorder later proved to
be due to ‘contamination’ by spinal cord components in the
inoculum. The EAE model has since evolved a long way;
different variants, mice, rats or non-human primates are
immunized with whole spinal cord, myelin proteins or
even deﬁned peptides, usually in complete Freund’s adjuvant
(CFA). This immunization leads to a disease that shares clin-
ical and neuropathological changes with multiple sclerosis
(Steinman, 1999). The course it takes ranges from acute
monophasic (or even lethal) to chronic progressive or
relapsing–remitting (Steinman, 1999). Typical CD4
+ TH1
myelin-speciﬁc T cells have been implicated as the
disease-initiating subset. In almost all models, they are sufﬁ-
cient to induce EAE; they can be isolated, cloned and used to
transfer disease to naı ¨ve healthy animals (Zamvil and
Steinman, 1990). These various EAE models have been
used to dissect molecular mechanisms of the autoimmune
inﬂammatory response, and hence to devise and test new
therapies for multiple sclerosis. It is clear, however, that
the artiﬁcial induction of a myelin-speciﬁc immune response
may by-pass key pathogenetic mechanisms operating in
human disease, as we do not even know the key target auto-
antigens in multiple sclerosis.
Limitations of current EAE models
Without doubt, EAE models are vital for studying general
concepts as well as speciﬁc processes of autoimmunity, how-
ever rarely they predict success in clinical trials (see below).
Nevertheless, their value is further challenged by our rudi-
mentary understanding of the key pathogenetic mechanisms
in EAE models, and their failure to forewarn us of adverse
effects (reviewed below). As with other murine disease
models, including the NOD model of type 1 diabetes
(Roep et al., 2004), it appears much easier to prevent, reverse
or ameliorate EAE in mice than multiple sclerosis in man.
Furthermore, since EAE almost always has to be induced, it
cannot mimic a spontaneous disease. The most important
component in the inducing adjuvant CFA is heat-inactivated
Mycobacterium tuberculosis, which always induces a promi-
nent CD4
+ TH1 response by activating certain toll-like recep-
tors (Su et al., 2005). This leaves little room for variability in
disease pathways and certainly does not reﬂect heterogeneous
inducing mechanisms in multiple sclerosis. Also, demyelina-
tion is not obvious in all models. Moreover, the time courses
are very different. Since EAE develops over days in most
models, they seem more similar to post-infectious acute
demyelinating events (Steinman, 1999). Indeed, the mice
are rarely monitored for late relapses and fatal adverse effects,
such as those noted in marmosets (Genain et al., 1996).
Nevertheless, the same treatment can have a different degree
of efﬁcacy or even opposite effects at different stages in EAE,
as has also been reported for other autoimmune models such
as in NOD mice (Shoda et al., 2005). In contrast, multiple
sclerosis usually manifests insidiously over years, for example,
in its relapsing–remitting and later chronic forms
(Noseworthy et al., 2000a), by when antibodies and comple-
ment may also be more important than in most mouse mod-
els. Indeed, many patients present after much more
protracted epitope spreading than is usually seen in EAE
mice (Vanderlugt and Miller, 2002). These and other obvious
mouse : human differences are summarized in Table 1.
Many aspects of pathology and immunology differ between
multiple sclerosis and EAE. These differences are fundamen-
tal, as ongoing imbalances in immune regulation must be
crucial for the progression of multiple sclerosis; such orders
of complexity have not yet been recapitulated in EAE models.
What can we learn from failures or
successes in adapting therapies from
EAE to multiple sclerosis?
Only very few therapeutics that were successful in pre-clinical
EAE trials have shown similar efﬁcacy in multiple sclerosis
The value of animal models for drug development in multiple sclerosis Brain (2006), 129, 1940–1952 1941
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 patients; the majority of new treatments were either less
effective in these patients, worsened disease or caused severe
adverse events. In Table 2 we list a subset of these therapies
reﬂecting this discrepancy.
Antigen-speciﬁc therapies
Only one licensed multiple sclerosis therapy (Glatiramer
acetate, GA), a synthetic amino acid copolymer (Glu, Ala,
Lys and Tyr), emerged from ﬁndings in EAE (Teitelbaum
et al., 1971). It was designed to mimic encephalitogenic mye-
lin basic protein (MBP) epitopes, but instead it suppresses
EAE by other mechanisms in several species, and it reportedly
reduces multiple sclerosis relapses by 30% (Johnson et al.,
1995). GA has many biological activities including bystander
suppression via induction of TH2 cells that partly cross-react
with MBP, and/or upregulation of CNS growth factors
(Arnon and Aharoni, 2004). However, its in vivo mechanisms
are not clear and even its beneﬁcial effects on the main out-
come measures in multiple sclerosis (disease progression)
have now been questioned in a systematic Cochrane review
(Munari et al., 2004).
A more speciﬁc therapeutic approach in EAE and multiple
sclerosis has been based on an altered peptide ligand of MBP
85–99 that was modiﬁed at its main T-cell receptor (TCR)
contact sites (Brocke et al., 1996). Despite promising effects
in EAE, subcutaneous administration of altered peptide
ligand at high doses led to multiple sclerosis exacerbations
in some patients, which could be linked to this treatment
(Bielekova et al., 2000). A trend towards improved MRI
parameters was observed in another phase II trial (Kappos
et al., 2000), and an additional phase II study is under way. Its
success in EAE may depend on the stereotyped TH responses
of inbred mice.
Oral administration of myelin antigens leads to speciﬁc
immune hyporesponsiveness in mice. Different doses and
feeding regimes have been demonstrated to induce different
types of ‘oral tolerance’/degrees of immune suppression in
different EAE models (Faria and Weiner, 2005). ‘Bystander
suppression’ directed against one tolerogen may suppress
reactions against other myelin antigens in situ, a major advan-
tage where the key autoimmunizing antigen(s) are not
known. However, a large double-blind phase III trial of a
single oral dose of bovine myelin in RR multiple sclerosis
did not show differences in the number of relapses between
placebo and treated groups (Faria and Weiner, 2005). Treat-
ment failure could have been due to the unexpectedly strong
Table 1 Immunological differences between mouse and human relevant for testing multiple sclerosis therapeutics
Mouse Human References
General Inbred; homozygous Outbred; heterozygous
Short lifespan: high fecundity Long lifespan: low fecundity
Fixed diet; pathogen-free Varieddiet; carriers ofpotential pathogens,
e.g. EBV, JCV etc
Clean environment Open access to new infections
EAE and multiple sclerosis
May be monophasic Different subtypes, usually relapsing
Mice tested while epitopes are
spreading
Epitopes must often have spread long
before diagnosis
Vanderlugt and Miller
(2002)
Induction Usually with CFA Spontaneous
Testing new therapeutics Induction of EAE studied much
more than ongoing disease
Ongoing disease
Only a few dozen mice tested Hundreds of multiple sclerosis patients;
some side-effects are too rare to be seen
in mice
Scrutiny Less detailed Detailed, would be missed in mice
Follow-up Often short-term only Several years or life-long
Molecular differences in immune response
T-cell responses Often stereotypical Usually idiosyncratic, even to
recurring epitope(s)
Lymphocytes in
peripheral blood
75–90% 30–50% Doeing et al. (2003)
CD4
+ expression Lymphocytes Lymphocytes, macrophages Crocker et al. (1987)
CD8
+ expression Lymphocytes, dendritic cells Lymphocytes Banchereau et al. (2000)
IL-10 expression TH2T H1 and TH2 Del Prete et al. (1993)
IFN-a response No preferential TH differentiation Promotes TH1 response Farrar et al. (2000)
IL-4 and IFN-g
expression by TH
Exclusively one or the other Sometimes both Gor et al. (2003)
CD28 expression 100%ofCD4
+andCD8
+Tcells 80% of CD4
+ Tcells, 50%of CD8
+Tcells Lenschow et al. (1996)
MHC class II expression Absent on T cells and
endothelial cells
Present on T cells and
endothelial cells
Choo et al. (1997),
Taams et al. (1999)
CD52 expression Not found in mice Lymphocytes Tone et al. (1999)
Glucocorticoid-sensitivity High Low and variable Claman (1972)
1942 Brain (2006), 129, 1940–1952 M. A. Friese et al.
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 effects in the placebo group, wrong dose or type of antigen, or
route of administration.
Adhesion molecules
Another promising strategy, using a blocking anti-a4 integrin
humanized antibody (natalizumab), emerged from EAE
evidence that a4b1 integrin is critical for T cell and monocyte
homing to the CNS (Yednock et al., 1992). This mAb was
highly effective in pre-clinical EAE studies and successfully
completed phase II and III testing in large numbers of multi-
ple sclerosis patients. Because of its remarkable efﬁcacy in
multiple sclerosis (Miller et al., 2003), natalizumab was
approved by the Food and Drug Administration even before
phase III trial data had been published, but was taken off the
market four months later because of rare but very severe
Table 2 Some immunomodulatory approaches of multiple sclerosis and their development from EAE or in vitro studies to
clinical application*
Treatment
approach
Based on
clear
hypothesis
Rationale
conﬁrmed
Efﬁcacy
in EAE
Efﬁcacy
in multiple
sclerosis
Adverse
event
proﬁle
Status of
development
Reference
Glatiramer acetate No No ++ + +++ Approved Johnson et al. (1995)
Altered peptide
ligand
Yes No; i.d. ++ ; i.d. 6 No Bielekova et al. (2000),Kappos
et al. (2000)
Oral myelin Yes Yes ++  +++ Not continued after phase III
owing to lack of efﬁcacy
Faria and Weiner (2005)
Anti-a4 integrin Yes Yes +++ +++ 6
† Taken off the market Miller et al. (2003)
Anti-CD40L Yes Yes +++ n.k. 6 No Dumont (2002)
Anti-CD4 Yes No +++ 66 Halted in phase II van Oosten et al. (1997)
Anti-CD52 Yes Yes n.a. ++; i.d. + Approvedforother indication Coles et al. (1999b)
Anti-CD25 Yes No 6 +++; i.d. ++ Approvedforother indication Bielekova et al. (2004)
CTLA-4-Ig Yes No; i.d. +++ n.k. n.k. In phase III Kremer (2004)
IFN-b No No ++ + +Approved Paty and Li (1993)
IFN-g No No ++  Stopped in phase I Panitch et al., 1987)
Anti-TNF
antibodies
Yes No ++(?)  ‡ Approvedforother indication van Oosten et al. (1996)
TNFR-Ig fusion
protein
Yes No ++(?)  ‡ Approvedforother indication The Lenercept Multiple Sclerosis
Study Group and The University
of British Columbia multiple
sclerosis/MRI Analysis Group
(1999)
TGF-b2 Yes Yes ++ i.d.  Stopped in phase I Calabresi et al. (1998)
IL-10 Yes No 6 i.d. i.d. Stopped in phase II Wiendl et al. (2000)
IGF-1 Yes Yes +(+) ; i.d. ++ Phase IIa, not continued Frank et al. (2002)
PDE4 inhibitors Yes Yes ++ ; i.d. + Halted in phase II R.Martinetal.(unpublisheddata)
PPARg agonists Yes Yes ++ n.t. n.a. Not yet tested in multiple
sclerosis
Diab et al. (2002), Feinstein et al.
(2002)
Statins Yes Yes +++ ++; i.d. + Approved for other
indication
Vollmer et al. (2004), Youssef
et al. (2002)
Mitoxantrone No
§ No
§ ++ ++ 6 Approved Hartung et al. (2002)
Linomide No No ++ ++ 6 Phase III stopped due to
cardiotoxicity
Noseworthy et al. (2000c)
Laquinimod No No ++ ++; i.d. + In phase II Polman et al. (2005)
FTY720/SP-1
agonist
No No +++ ++(+); i.d. + In phase II Gonsette (2004), Rausch et al.,
2004)
Deoxyspergualin No No +  + After phase II stopped
owing to lack of efﬁcacy
Wiendl and Hohlfeld (2002)
Sulphasalazine Yes No 66 + In phase III Noseworthy et al. (1998)
IVIG No No 66 ++ In phase II Hommes et al. (2004), Sorensen
et al. (2002)
Haematopoietic
stem cell transplant
Yes Yes ++ + ;i.d. 6; i.d. In phase III Mancardi et al. (2005), Tyndall
and Saccardi (2005)
i.d., insufﬁcient data; n.a., not applicable; n.k., not known; n.t., not tested; *The table depicts whether a therapeutic approach was developed
for multiple sclerosis on the basis of a clear and pre-formed hypothesis, whether the rationale for its clinical/EAE testing had later been
shown and whether the therapy was effective in EAE and/or multiple sclerosis. Both the clinical efﬁcacy and the tolerability and safety are
depicted by + or  signs. In the context of the adverse events, + indicates a favourable proﬁle. The relative weighting reﬂects the subjective
perception of the authors either from own experience or the published literature;
†Reasonable safety proﬁle, but one speciﬁc severe
adverse event (PML).
‡Development of demyelinating episodes and diseases in RA- and Crohn’s patients;
§Broad immunosuppressant; no
speciﬁc target.
The value of animal models for drug development in multiple sclerosis Brain (2006), 129, 1940–1952 1943
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 adverse events. Three patients had developed progressive
multifocal leukoencephalopathy (PML), an often lethal
opportunistic infection of the CNS; two died, and one is
recovering, though with considerable neurological deﬁcits
(Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould
et al., 2005; Van Assche et al., 2005). A large post facto analysis
estimated the risk of PML for a 2-year treatment period to
1 in 1000 patients (Yousry et al., 2006). PML is caused by
reactivation and mutation of the highly prevalent polyoma-
virus JC (JCV), which destroys oligodendrocytes. PML is
almost exclusively observed in immunosuppressed indivi-
duals, and it is not clear what initiated its unexpected deve-
lopment under natalizumab treatment. JCV persists in
kidneys and lymphoid organs, including bone marrow
(Monaco et al., 1998). During immunosuppression, latent
infection can be reactivated, and JCV disseminates to the
CNS (Tornatore et al., 1992). That might have resulted either
from compromised T-cell surveillance of the CNS or from
mobilization of stem cells and JCV from the bone marrow
(Papayannopoulou and Nakamoto, 1993; Ransohoff, 2005),
where a4b1 integrin serves as a retaining signal (Simmons
et al., 1992). Since JCV is not found in rodents, this adverse
event could not have been anticipated from pre-clinical inves-
tigations. Therefore, this drug cannot be called a failure of
prediction, especially as many thousand patients needed to be
treated to unravel potential adverse effects. In addition, the
recently published two-year phase III trials underline its com-
pelling effects on relapse rate and clinical progression
(Polman et al., 2006; Rudick et al., 2006). In March 2006,
The Peripheral and CNS Drugs Advisory Committee, under
The Food and Drug Administration, voted unanimously to
recommend the return of natalizumab for the treatment of
RR multiple sclerosis in a subset group of patients.
Co-stimulatory molecules
Despite its promise in EAE, anti-CD40 ligand (CD154)
(Howard et al.,1999)was not developed because of its throm-
boembolic complications in man (Kawai et al., 2000), which
result from its expression on human but not murine platelets.
Anti-CD4 therapy was effective in EAE (Waldor et al., 1985),
but not in human studies (van Oosten et al., 1997).
Anti-CD52, which depletes both CD8
+ and CD4
+ T-cells
(Coles et al., 1999b), was never evaluated in EAE, but is
very effective against new lesions in multiple sclerosis, though
30% of treated multiple sclerosis patients develop auto-
immune hyperthyroidism (Coles et al., 1999a). On the
other hand, IL-2 receptor blockade with the humanized
anti-CD25 antibody (daclizumab) caused impressive reduc-
tions in MRI lesions and improvements in some clinical
measures (Bielekova et al., 2004). In this case, the theoretical
role of CD25 in promoting T regulatory cells, and equivocal
EAE data (Engelhardt et al., 1989; Reddy et al., 2004), might
have argued against its use in multiple sclerosis. Interestingly,
there is little evidence that it perturbs T regulatory or TH
function; indeed it may act by expanding immunoregulatory
NK cells (Bielekova et al., in review). CTLA-4-Ig interferes
with co-stimulation from CD80/CD86 molecules on antigen-
presenting cells (APCs) to the stimulatory or inhibitory
ligands CD28 and CTLA-4 (Alegre et al., 2001). Data in
EAE indicate that CTLA-4-Ig is much more effective as a
preventive pre-treatment (Cross et al., 1995) than in therapy
of ongoing disease (Cross et al., 1999). Treatment with
CTLA-4-Ig is also effective in other autoimmune diseases
such as rheumatoid arthritis (Kremer et al., 2003), and is
currently being tested in a phase III trial in multiple sclerosis.
Cytokines
Cytokines have different effects at different stages of patho-
genesis, for example, in the induction phase and the chronic/
relapsing phase in EAE. These differences suggest a pleiotro-
pic role in CNS inﬂammation and might explain some of the
below-described discrepancies between EAE and multiple
sclerosis.
Interferon-b ( IFN-b), the ﬁrst drug approved for multiple
sclerosis, had not been previously tested in EAE. It exerts a
wide variety of effects on the immune system: it inhibits both
leukocyte proliferation and antigen presentation; it biases
towards production of anti-inﬂammatory cytokines and it
inhibits T-cell migration across the blood-brain barrier
(Billiau et al., 2004). Although widely used in multiple sclero-
sis, its long-term effectiveness and side-effects are still uncer-
tain (Filippini et al., 2003). With other cytokines, effects have
seemed contradictory in EAE vis a ` vis multiple sclerosis. In
the mid-1990s, it was found that IFN-g knockout mice
develop lethal EAE (Ferber et al., 1996), and IFN-g admin-
istration in EAE showed a protective effect on disease severity
(Krakowski and Owens, 1996). By then, its use in multiple
sclerosis patients had already led to a modest increase in
disease exacerbations (Panitch et al., 1987). Although this
study is limited, it is unlikely that IFN-g will ever be tested
again in multiple sclerosis.
In contrast, tumour necrosis factor-a (TNF-a) has long
been considered a key mediator of multiple sclerosis patho-
genesis (Sharief and Hentges, 1991), and its blockade by
antibodies or soluble TNF receptors prevents or reverses dis-
ease in EAE models (Ruddle et al., 1990; Selmaj et al., 1991,
1995). Paradoxically, this approach worsens disease in multi-
ple sclerosis patients and had to be discontinued (The Lener-
cept Multiple Sclerosis Study Group and The University of
British Columbia Multiple Sclerosis/MRI Analysis Group,
1999; van Oosten et al., 1996). Indeed, a substantial number
of cases developed their ﬁrst demyelinating event while being
treated with anti-TNF-a agents for other diseases such as
rheumatoid arthritis or Crohn’s disease (Hyrich et al.,
2004). Despite the data that TNF-a is an important compo-
nent in the pathogenesis in EAE, a precise role for TNF-a in
multiple sclerosis remains unclear. However, subsequent EAE
experiments using TNF-a gene deleted mice (TNF-a
/)
surprisingly showed that TNF-a
/ mice displayed profound
neurological impairment and high mortality with extensive
1944 Brain (2006), 129, 1940–1952 M. A. Friese et al.
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 demyelination and monocytic cell inﬁltration in comparison
with control mice (Liu et al., 1998). Conversely, treatment of
the TNF-a
/ mice but also wild-type mice with recombi-
nant TNF-a reduced disease severity in afﬂicted mice and
prevented development of EAE in pre-treated mice. These
studies suggested that TNF-a may be protective in the
CNS during the development of demyelinating disease also
in mice and may serve to limit the extent of immune-
mediated inﬂammation, as was implicated by the study in
multiple sclerosis patients. Further, we can only speculate on
the reasons for the adverse outcome of TNF-blocking
approaches in multiple sclerosis, but it has been demon-
strated that TNF signalling is also important for remyelina-
tion (Arnett et al., 2001; Diemel et al., 2004).
Transforming growth factor (TGF)-b2 ameliorates EAE
and is a very potent immunosuppressive cytokine. However,
it has never been approved as a treatment in multiple sclero-
sis, as it is associated with nephrotoxicity in multiple sclerosis
patients, which was not checked in EAE (Calabresi et al.,
1998). Interleukin (IL)-10 is another important suppressive
cytokine, produced mainly by regulatory CD4
+ T cells
(O’Garra et al., 2004). Its selective upregulation in the
CNS during the recovery phase of EAE prompted the evalua-
tion of IL-10 treatment in a Lewis rat EAE model. Systemic
administration during the initiation phase suppressed EAE
disease (Rott et al., 1994). Again IL-10 treatment in a phase II
clinical trial in multiple sclerosis patients had to be stopped,
owing to lack of efﬁcacy (Wiendl et al., 2000).
Neurotrophic factors
Apart from cytokines, several neurotrophic factors have been
proposed as a novel therapeutic in multiple sclerosis. These
proteins regulate survival and differentiation of neurons by
binding to speciﬁc neurotrophin receptors (Thoenen and
Sendtner, 2002). They are involved in skewing the cytokine
balance in the CNS from TH1t oT H2 responses (Villoslada
et al., 2000), and neuroprotective effects have been proposed
(Hohlfeld et al., 2005). The clinical potential of one such
factor, insulin-like growth factor-1 (IGF-1), was ﬁrst studied
in a rat EAE model, in which myelin regeneration and clinical
recovery was enhanced (Yao et al., 1995). In contrast, there
was no clear effect in one phase-I/II study in seven patients
(Frank et al., 2002).
Anti-inﬂammatory substances,
immunosuppression and
immunomodulation
Cytokine secretion and proliferation of T cells are regulated
by intracellular cyclic AMP (cAMP) levels, which are reduced
by phosphodiesterases (PDEs). The type 4 PDE (PDE4) is a
cAMP-speciﬁc phosphodiesterase expressed in cells of the
immune system and the CNS (Engels et al., 1994). Inhibition
of PDE4 activity by rolipram ameliorates EAE severity
(Sommer et al., 1995). It was originally developed and
evaluated in clinical studies as an anti-depressant (Zeller
et al., 1984). Since rolipram and other PDE4 inhibitors
(Dinter et al., 2000) demonstrated efﬁcacy in various EAE
models, it seemed a promising candidate for clinical use in
multiple sclerosis patients. However, a phase II clinical trial
was halted owing to lack of efﬁcacy on the primary outcome
measure, that is, the reduction of gadolinium-enhancing
inﬂammatory CNS lesions by MRI (Martin, R., Bielekova, B.,
Stu ¨rzebecher, C.S., Richert, N., Frank, J.A., Ohayon, J.,
McCartin, J., McFarland, H.F., unpublished data).
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily of
ligand-activated transcriptional factors that include receptors
for steroids, thyroid hormone, vitamin D and retinoic acid
(Mangelsdorf et al., 1995). PPAR-g is expressed in adipose
tissue, on macrophages, T cells, and endothelial and vascular
smooth muscle cells. The natural 15-deoxy-D
12,14-PGJ2
(15d-PGJ2) and the synthetic anti-diabetic thiazolidinedione
are PPAR-g ligands; their administration before and at the
onset of clinical signs of EAE signiﬁcantly reduced its severity
(Diab et al., 2002). Another orally administered PPAR-g
agonist pioglitazone reduced the incidence and severity in
C57BL/6 EAE and B10.Pl murine models. Pioglitazone also
reducedclinicalsignswhengivenafterdiseaseonset(Feinstein
et al., 2002). So far there is only casuistic information about
PPAR-g agonists in multiple sclerosis (Pershadsingh et al.,
2004), but clinical trials are being planned.
Statins block the enzyme 3-hydroxy-3-methylglutaryl-
coenzyme A reductase; they are widely used to lower choles-
terol levels and prevent cardiovascular disease. They are
highly effective in reversing EAE, shifting the pro-
inﬂammatory TH1-type cytokine proﬁle to a TH2-type
pattern and also interfering with antigen presentation
(Youssef et al., 2002). In this case, exploratory trials in multi-
ple sclerosis patients have shown promising results with up to
44% reduction in the number of contrast-enhancing MRI
lesions (Vollmer et al., 2004), so they are a solitary success.
Mitoxantrone is a potent anti-inﬂammatory cytostatic
anthracenedione, and suppresses both B and T lymphocytes
and macrophages, resulting in down-modulation of the
inﬂammatory cascade. Since it had already been approved
for the therapy of malignancies, this immunosuppressant
could logically have been assessed in multiple sclerosis with-
out studying EAE. Not surprisingly, mitoxantrone has potent
effects in EAE. It suppressed paralysis in acute EAE, prevented
its development when administered during the induction
period and still showed some effects when given after clinical
signs and symptoms appeared (Ridge et al., 1985; Levine and
Saltzman, 1986). These results parallelled recent proof of
efﬁcacy in multiple sclerosis (Hartung et al., 2002). However,
cardiotoxicity was a reported adverse effect in humans;
though not observed in the early EAE studies (Ridge et al.,
1985; Levine and Saltzman, 1986), it was also detected in
careful retrospective analysis in treated mice. Meanwhile,
the more serious problem of inducing haematopoietic malig-
nancies is predictable for a cytotoxic agent, and has already
The value of animal models for drug development in multiple sclerosis Brain (2006), 129, 1940–1952 1945
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 been reported in multiple sclerosis patients, though not in
rodents (Cohen and Mikol, 2004). An estimate of 0.07% has
been reported on the basis of a review of over 1 300 patients
(Ghalie et al., 2002).
Linomide and laquinimod are immunoregulatory compo-
nents with yet-unidentiﬁed mechanisms of action. Both are
quinoline carboxamides with structural homology to trypto-
phan metabolites (Platten et al., 2005). Linomide (Karussis
et al., 1993) and laquinimod (Brunmark et al., 2002) effec-
tively inhibit and even reverse EAE, and show some efﬁcacy in
patients with multiple sclerosis (Noseworthy et al., 2000c;
Polman et al., 2005). However, a phase II clinical trial of
linomide in patients with multiple sclerosis was halted
because of serious concerns that some quinoline carboxa-
mides are cardiotoxic (Noseworthy et al., 2000c). A recently
described additional orally active derivative of a tryptophan
metabolite, N-(3,4,-dimethoxycinnamoyl) anthranilic acid
(3,4-DAA), reversed paralysis in mice with EAE (Platten
et al., 2005). However, as it is proposed that these metabolites
act similarly to quinoline carboxamides and, as tryptophan
metabolism is an ubiquitous process, concerns remain about
their use in multiple sclerosis.
FTY720 is a structural analogue of myriocin, a metabolite
of the ascomycete fungus Isaria sinclairia, with some struc-
tural resemblance to sphingosine, an endogenous lysolipid.
Sphingosine phosphorylation by sphingosine kinase gener-
ates sphingosine-1-phosphate (S1P), the cognate ligand for
the family of S1P receptors (S1PR) (Rosen and Goetzl, 2005).
Their activation results in many different physiological
actions such as chemotaxis, cellular differentiation, survival
and growth, cell adherence and cell shape changes (Rosen and
Goetzl, 2005). At least one action of S1P is to sequester
circulating lymphocytes in peripheral lymph nodes, leading
to a sustained lymphopenia (Schwab et al., 2005; Wei et al.,
2005). FTY720 was able to suppress EAE development in
different models (Brinkmann et al., 2002; Fujino et al.,
2003; Webb et al., 2004). However, its success in EAE was
not surprising as FTY720 is a broadly active immunosuppres-
sant (Gonsette, 2004). It is now being tested in a 6-month
phase I/II clinical trial in multiple sclerosis. As it suppresses
the egress of lymphocytes from lymph nodes, one has to
monitor these patients for signs of infection. In addition,
S1PR is highly expressed in myocytes of the myocardium
and regulates the heart rate (Sanna et al., 2004), so brady-
cardia is one adverse effect in treated patients (Budde et al.,
2003), and has also been observed in mice (Sanna et al.,2004).
Forunknownreasons,FTY720canalsocausemacularoedema.
Another immunosuppressive drug, deoxyspergualine
(DSG), is an analogue of the bacterial product spergualin
from the soil commensal Bacillus lactosporus (Maeda et al.,
1993). The molecular mechanism underlying its pharmaco-
logical effects remains elusive; it is still not clear whether its
inhibitory effect on pre-B- and pre-T-cell differentiation is
due to the interference with NF-kB family members (Wang
et al., 1996). DSG was tested in EAE models and has shown
potent immunosuppressive actions, delaying onset and redu-
cing severity of clinical symptoms (Schorlemmer and Seiler,
1991). However, its pronounced effect on pre-B- and pre-
T-cell development (Wang et al., 1996) appears to cause
serious problems with peripheral lympho-depletion. Again,
a phase II clinical trial in multiple sclerosis was started but
had to be stopped owing to lack of efﬁcacy (Wiendl and
Hohlfeld, 2002).
Sulphasalazine has been used for decades in the treatment
of rheumatoid arthritis and inﬂammatory bowel disease, but
its anti-inﬂammatory actions are still not clearly understood.
Reports on its effects in EAE have been conﬂicting, ranging
from beneﬁcial (Prosiegel et al., 1989, 1990) to neutral
(Uitdehaag et al., 1991) or deleterious (Correale et al.,
1991). A randomized, double-blind, placebo-controlled
phase III trial showed no signiﬁcant improvement in multiple
sclerosis progression (Noseworthy et al., 1998), while another
phase III trial is currently under way.
The puriﬁed immunoglobulins administered intravenously
as IVIG may act via Fcg receptors and so deliver inhibitory
signals to various immune cells (Nimmerjahn and Ravetch,
2006). Clearly effective in Guillain–Barre syndrome when
given early, IVIG also had signiﬁcant positive effects on
both disease course and CNS inﬂammation in EAE, but
only when administered at the time of immunization
(Pashov et al., 1998; Achiron et al., 2000). Positive effects
have also been well described in RR multiple sclerosis
(Sorensen et al., 2002). However, it did not reverse long-
standing motor deﬁcits in patients with established
weakness (Noseworthy et al., 2000b) and had no signiﬁcant
effect in SP multiple sclerosis patients (Hommes et al.,
2004).
Transplantation and reconstitution
Immune ablation plus autologous haematopoietic stem cell
transplantation (auto-HSCT) have been proposed as an
experimental therapy for patients with severe multiple
sclerosis (Muraro et al., 2003; Fassas and Kimiskidis, 2004).
As in other autoimmune diseases, the goal is to eliminate the
pathogenic lymphocyte repertoire (Sykes and Nikolic, 2005)
and ‘re-boot’ the immune system to restore immune toler-
ance, halt ongoing inﬂammatory activity and prevent further
relapses. In practice, the chances of reconstituting thymopoi-
esis are higher before than after the age of 45 years old.
Susceptible mice can also be protected from autoimmune
diseases by transfer of HSCT from resistant allogeneic strains;
such allo-HSCT prevented the development of EAE (Sykes
and Nikolic, 2005). The extent of remission of ongoing EAE
was greater with allo- than with auto-HSCT (van Gelder and
van Bekkum, 1996). At early stages, auto-HSCT produced
nearly complete reversal of disease, but no effect was observed
at chronic stages (Guillaume et al., 1998; Van Bekkum, 2003;
Herrmann et al., 2005).
In multiple sclerosis, multiple clinical trials of high-dose
immunosuppression/chemotherapy plus auto-HSCT have
been started (Saccardi et al., 2005). Initial results appear
1946 Brain (2006), 129, 1940–1952 M. A. Friese et al.
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 more promising than that would have been predicted from
the ﬁndings in EAE (Mancardi et al., 2005; Tyndall and
Saccardi, 2005). While the death rate was disturbingly high
in one trial (5 out of 85 treated patients) (Tyndall and
Saccardi, 2005), it can apparently be reduced by paying care-
ful attention to the patient’s disease stage and disability as
well as the conditioning regime (Saccardi et al., 2004) and
CD34
+ cell preparation (R. Saccardi et al., manuscript
submitted).
As shown in Table 2, there have been signiﬁcant problems
in multiple sclerosis with virtually all the agents that appeared
beneﬁcial in EAE. Even when efﬁcacy has been replicated in
the human disease, additional unexpected adverse effects
appeared. These have precluded successful clinical applica-
tion in nearly every case, as often happens in the development
of any drug. The recent fatal adverse events in clinical trials of
natalizumab (Kleinschmidt-DeMasters and Tyler, 2005; Van
Assche et al., 2005) seem particularly tragic in a disease of
young adults that is not life-threatening and runs a very long
course. Adequate prediction of toxicity remains a funda-
mental issue for all forms of drug development, and current
rodent EAE models cannot be expected to eliminate these
problems.
Worse still, however, many of the EAE results have been
actively misleading. Therefore, it is difﬁcult to claim any
predictive value from positive pre-clinical ﬁndings in
‘conventional’ EAE models. Although outbred humans and
inbred mice may only differ by 300 genes (Waterston et al.,
2002), their immune systems must have evolved differently
because of their different ecology and lifestyles, their different
pathogenic challenges and their different size, fecundity and
longevity (Mestas and Hughes, 2004). The many similarities
between the two immune systems have lulled us into
overlooking these differences and into assuming identical
functions for certain molecules in each species (Table 1).
As one relevant example, steroid-sensitivity is 100 times
greater in mice than in humans, where it clearly also varies
greatly between subjects (Claman, 1972).
Rethinking pathophysiological concepts of
EAE and multiple sclerosis
One crucial question is how well EAE models replicate the
induction and pathogenic mechanisms in multiple sclerosis.
Obviously, these would need to be accurately understood
before optimal models could be developed. Furthermore,
since EAE almost always has to be induced, it is of very
limited value as a model for a spontaneous human demye-
linating disease.
It now transpires that the currently favoured therapeutic
concepts in multiple sclerosis—which nearly all depend on
targeting CD4
+ TH1 cells—are based on debatable founda-
tions that demand to be re-examined. While it has been
accepted for many years that EAE is largely a CD4
+ TH1-
mediated disease (Zamvil and Steinman, 1990), it probably
reﬂects the use of CFA in nearly all models. It is now also
challenged by the observation that other T-cell populations
including TH2 CD4
+ T cells (Lafaille et al., 1997) and CD8
+
myelin-speciﬁc T cells (Huseby et al., 2001) can also mediate
EAE, depending on the model used. In addition, a new
CD4
+IL-17
+ subset has been shown to mediate EAE after
adoptive transfer (Langrish et al., 2005). This cell subpopula-
tion is distinct from TH1 and TH2 populations, and its dif-
ferentiation might be driven by APCs expressing IL-23
(Harrington et al., 2005; Langrish et al., 2005; Park et al.,
2005), while others did not ﬁnd a role for IL-23 in differ-
entiation but report a combination of TGF-b and IL-6,
ampliﬁed by IL-1b and TNF-a to be instrumental
(Veldhoen et al., 2006); after selective depletion of
CD4
+IL-17
+ T cells, the remaining cells no longer induce
EAE after transfer (Langrish et al., 2005). Thus, its apparently
exclusive role in EAE pathogenesis may help explain some
contradictory results, if it also proves to predominate in a
wider range of EAE models.
While these ﬁndings challenge the current dogma that EAE
is mediated solely by TH1-cells, those are still implicated
by many data from multiple sclerosis patients—for example,
by their increased numbers and higher antigen avidity
(Sospedra and Martin, 2005). However, other subsets such
as CD8
+ T cells outnumber CD4
+ T cells 3–10-fold in multi-
ple sclerosis plaques (Hauser et al., 1986; Babbe et al., 2000),
and oligoclonal CD8
+ T-cell populations are present in multi-
ple sclerosis brain, blood (Babbe et al., 2000) and CSF
(Jacobsen et al., 2002); moreover, IL-17 is found in multiple
sclerosis plaques (Lock et al., 2002). While there is already
much evidence to incriminate CD8
+ Tcells in multiple sclero-
sis (Friese and Fugger, 2005), it still needs more support.
Indeed, it remains possible that different subsets play key
roles at different stages, and that some of these may differ
between multiple sclerosis and many EAE models. Thus, we
suspect that CD4
+ TH1 or CD4
+IL-17
+ cells are indeed crucial
for initiation, whereas CD8
+ T cells may be more important
in the effector phase. Although certain ﬁndings show clear
similarities in multiple sclerosis and EAE, translating the
above knowledge on the involvement of novel T-cell popula-
tions to multiple sclerosis will pose new challenges due to
species-speciﬁc differences between mouse and man—which
clearly demands further studies.
New concepts for development of
EAE models
To develop improved animal models that reﬂect the patho-
genesis of multiple sclerosis better, one has to remember that
multiple sclerosis is highly heterogeneous in its genetic basis,
environmental effects, clinical course, pathological mechan-
isms (Lassmann et al., 2001) and treatment responsiveness.
This heterogeneity needs to be comprehended in any ideal
animal model (Box 1). Currently, they almost invariably use
inbred strains, although the molecular interactions that
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 determine the efﬁcacy, metabolism and safety of drugs
during prolonged follow-up of thousands of patients are
orders of magnitude more complex. Thus, it is likely that
genetic heterogeneity, at least in part, accounts for many
inter-patient differences in clinical beneﬁts and side-effects
of various drugs.
Potential therapeutics need to be tested in models that,
together, mimic both this heterogeneity and the main
pathological mechanisms including inﬂammation, demyeli-
nation, axonal damage and glial scarring. That is seldom
attempted in current models; at best, one inbred strain
might correspond to one multiple sclerosis patient, perchance
with a comparable genetic background.
Recently developed partially humanized mouse models are
a signiﬁcant ﬁrst step towards addressing this genetic varia-
bility and disease complexity (Gregersen et al., 2004). Par-
tially humanized mice, transgenic for human MHC-class II
and a TCR from a multiple sclerosis patient’s myelin-speciﬁc
TH clone, are beginning to reproduce some of the various
clinical manifestations and corresponding CNS lesions of
multiple sclerosis. For example, disease appears sponta-
neously in 4% of mice transgenic for both HLA-DR2
(DRB1*1501) and the TCR from multiple sclerosis patient
Ob, which is speciﬁc for HLA-DR2 (DRB1*1501)-bound
immunodominant MBP 84-102 peptide (Madsen et al.,
1999), so do mice transgenic for the other DR2 allele,
DRB5*0101, and the multiple sclerosis patient-derived
MBP 83-99-speciﬁc TCR 3A6 (Quandt, J., Yao, K., Huh,
J., Baig, M., Kawamura, K., Bryant, M., McFarland, H.,
Martin, R., Ito, K., unpublished results). After backcrossing
onto a Rag2
/ background (for recombination-activating
gene 2), the incidence of spontaneous disease was much
higher (Madsen et al., 1999), hinting at differences in regula-
tion. Moreover, on both backgrounds, it affected the
brain relatively more than the spinal cord, unlike in conven-
tional EAE. A different clinicopathological picture is seen
in another model instead using HLA-DRB1*0401 and the
TCR from T-cell clone MS2-3C8 isolated from a multiple
sclerosis patient reactive to MBP 111–129 (Quandt et al.,
2004). These mice show dysphagia with restricted jaw and
tongue movements and abnormal gait, and correspondingly
more speciﬁc T-cell inﬁltrates and inﬂammatory lesions
in the brainstem and cranial nerve roots in addition to
the spinal cord and spinal nerve roots (Quandt et al.,
2004). Thus, models that incorporate multiple susceptibi-
lity factors may reproduce the clinical heterogeneity of
multiple sclerosis better, and perhaps improve identiﬁcation
of promising therapeutic approaches. Since they are still far
from giving a complete picture, they need to be extended.
Stem cell technology may allow more complete humaniza-
tion; for example, using human haematopoietic stem cells to
reconstitute the immune system in mice (Gimeno et al., 2004;
Traggiai et al., 2004; Shultz et al., 2005) may advance model-
ling of multiple sclerosis and improve pre-clinical develop-
ment. Eventually, after due ethical reﬂection, it might become
possible to develop murine models in which both the
immune system and at least some components of the CNS
(e.g. oligodendrocytes, endothelium) share human origins. It
might be wise ﬁrst to assemble ‘generically humanized’ strains
with a human haematopoietic system, and then to incorpo-
rate multiple sclerosis-speciﬁc susceptibility alleles and TCRs.
By reducing species-imposed restrictions in identifying
drug targets, such mice might enable us to test larger numbers
of drugs than in the existing models. They should also be
susceptible to many more human pathogens, and may there-
fore help us in investigating their involvement in triggering
disease in susceptible individuals, in shaping its course and/or
in causing severe adverse events, if kept in a non-speciﬁc
pathogen-free environment.
Conclusions
In multiple sclerosis, at least two main components appear
important for the disease process: immunological abnorma-
lities, and susceptibility of the target tissue. Both compo-
nents can interact with a variety of different pathogenic
causes, depending on the environment and genetic back-
ground, resulting in the substantial heterogeneity that we
observe at every level of the disease. At present, it remains
unclear exactly why pre-clinical EAE studies predict treat-
ment efﬁcacy so poorly in multiple sclerosis. ‘Conventional
EAE’ will continue to play an important role as a ﬁrst-line
model system in the development of novel treatment
approaches, especially for addressing very speciﬁc mechan-
istic questions, as long as the rodent–human similarities or
dissimilarities are borne in mind. To approach the complex-
ity of multiple sclerosis patients, current progress in huma-
nizing the entire immune system in rodents may offer
substantial advantages for exploring novel immunomodula-
tory approaches in better suited models, especially after
incorporation of multiple sclerosis-speciﬁc susceptibility
alleles. While such models should substantially help in iden-
tifying promising therapies, we will probably always need
carefully designed early clinical trials that include imaging
outcome measures and mechanistic studies to assess their
actions in patients.
Box 1. Future considerations for improving animal
models for multiple sclerosis
 Validate therapeutic effect in more than one model
 Consider dissimilarities in immune systems of
rodents versus humans
 Consider treatment after disease onset
 Record disease course for as long as possible (feasible)
 Establishment of spontaneous disease models
 Establishment of a two-stage disease course in EAE
(ﬁrst relapsing–remitting, later chronic-progressive)
 Incorporate human disease risk factors
 Incorporate human immune system and modifying
human CNS factors
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